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Prognostic Role of Serum Chloride Levels
in Acute Decompensated Heart Failure
Justin L. Grodin, MD, Jennifer Simon, BA, Rory Hachamovitch, MD, Yuping Wu, PHD, Gregory Jackson, MD, 
Meghana Halkar, MD, Randall C. Starling, MD, MPH, Jeffrey M. Testani, MD, MTR, W.H. Wilson Tang, MD
H eart failure (HF) is often complicated byelectrolyte abnormalities. As ventriculardysfunction progresses to symptomatic
HF, up-regulation of maladaptive neurohormonal sys-
tems may limit solute and free water delivery to the
distal nephron, increasing free water absorption and
potentially reducing serum sodium and chloride levels
(1,2). These electrolyte perturbations may be exacer-
bated through the use of decongestive therapies in
acute and chronic HF (e.g., loop and thiazide diuretics)
(3–5). The finding of hyponatremia in the patient with
HF is a well-established, strong predictor of short- and
long-term morbidity and mortality irrespective of left
ventricular (LV) systolic function (6–13).
However, the impact of hypochloremia in HF is less
well understood despite its broad availability in
routinely used blood chemistry panels and its com-
mon attribution to contraction alkalosis during
excessive decongestion therapy. Further-
more, lower serum chloride levels relative to
sodium levels may identify an electrolyte-
deplete acute decompensated HF (ADHF)
phenotype with different prognostic conse-
quences. This study aimed to determine the
independent and incremental long-term
prognostic impact of admission serum chlo-
ride levels after hospitalization for ADHF.
METHODS
STUDY POPULATION AND DATA SYNTHESIS. The Cleve-
land Clinic Institutional Review Board approved this
study. We identified 1,318 unique, consecutive pa-
tients admitted to the internal medicine or cardiology
inpatient services at the Cleveland Clinic between
July 28, 2008, and December 31, 2013, with a
discharge diagnosis of ADHF. We confirmed the
discharge diagnosis by performing a search of the
International Classification of Diseases-Ninth Revi-
sion codes for acute or chronic HF (428.x). To further
improve the specificity of selecting an established
chronic HF population, only patients with a docu-
mented prior cardiac implantable electronic device
(implantable cardioverter-defibrillator [ICD] or car-
diac resynchronization therapy) were retained in the
registry. The presence of an ICD or cardiac resynch-
ronization therapy device was confirmed if there
was a prior medical encounter caused by such a de-
vice (V45.02), radiological examination suggesting
the presence of an ICD or cardiac resynchronization
therapy, electronic analysis of an ICD (including
interrogation, evaluation of generator status or pro-
gramming parameters, electrocardiographic analysis,
or a wearable cardioverter-defibrillator system), or
procedure in which there was a prior insertion or
repositioning of an electrode lead for a single-
or dual-chamber pacing ICD and insertion of a pulse
generator.
Patients were excluded if they were not given a
loop diuretic during admission, did not have an active
medication list, were <18 years of age, had prior heart
transplantation or mechanical circulatory assist de-
vice, or were on chronic dialysis therapy. Only the
first admission for a patient was included in the
cohort if they were subsequently readmitted. Long-
term all-cause mortality was determined from the
electronic medical record and validated, if possible,
by the Social Security Death Index. All patients were
followed until December 31, 2013.
VALIDATION COHORT. Charts of consecutive admis-
sions to noninterventional cardiology or internal
medicine services at the Hospital of the University of
Pennsylvania from 2004 to 2009 were reviewed. The
assembly and characteristics of patients in this cohort
have been previously described (14,15). Briefly, in-
clusion required a primary discharge diagnosis of
congestive HF, a hospital admission length between
3 and 14 days, and a B-type natriuretic peptide level
>100 pg/ml within 24 h of admission. Patients on
renal-replacement therapy were excluded from anal-
ysis, as were patients without documentation of
specific HF etiology, available blood chemistry values
at admission, or baseline medication use information.
As in the derivation cohort, in the case of multiple
admissions for a single patient, only the first admis-
sion was included. Clinical, demographic, imaging,
and laboratory data, and documented primary and
secondary diagnoses were reviewed from the elec-
tronic medical record. Admission chloride was
defined as the level on first blood draw on presenta-
tion; discharge chloride was determined using the
blood draw on the day of discharge. All patients were
followed until June 30, 2012, and death was verified
by the Social Security Death Index.
STATISTICAL METHODS. Continuous variables were
expressed as median (interquartile range) and cate-
gorical variables were expressed as percent. The
Jonkheere-Terpstra and Cuzick methods were used to
test trend across tertiles of admission chloride levels
for continuous and categorical variables, respectively
(16). Spearman correlation coefficients (r) were used
to show correlations between continuous variables.
Survival analyses were completed via the Kaplan-
Meier method and log-rank test to compare survival
curves across admission chloride tertiles. Cox pro-
portional hazards models were used to examine the
association between chloride levels and time to all-
cause mortality after adjusting for potential con-
founders. Hazard ratios (HRs) and 95% confidence
intervals (CIs) for all-cause mortality were determined
for all covariates. Proportional hazard assumption vi-
olations were estimated by generalized linear regres-
sion of scaled Schoenfeld residuals on time. For
proportional hazard violations (p < 0.1), “within-
stratum” estimates were provided for models strati-
fied by categorical variables, and Heaviside functions
were used to determine the time-dependency of risk
for continuous variables. The model covariates were
selected a priori (based on previous prognostic reports
in patients with HF and clinical experience) either
because of their prognostic relevance or their poten-
tial to confound the chloride-risk relationship. These
included admission sodium, blood urea nitrogen,
length of stay (days), age (years), ischemic cardiomy-
opathy, beta-blocker use, renin-angiotensin system
ABBR EV I A T I ON S
AND ACRONYMS
ADHF = acute decompensated
heart failure
CI = confidence interval
HF = heart failure
HR = hazard ratio
ICD = implantable
cardioverter-defibrillator
LV = left ventricular
inhibitor use, and mineralocorticoid antagonist use peptide) and indicators of end-organ function (he-
(17,18). The discrimination (C statistic) of the impact of moglobin and bilirubin). They were also inversely 
chloride levels on mortality was deter-mined as related to length of stay in the hospital and net weight 
previously described (19). Category-free net- change during admission. 
reclassification indexes and integrated discrimi- CHLORIDE LEVELS AND ALL-CAUSE MORTALITY. The 
nation improvement were calculated to further clarify Cleveland Clinic cohort of l ,3l 8 patients had 2,261 
the incremental prognostic value of chloride (20). 
Double-sided p values <0.05 were considered 
statistically significant. Statistical analyses were 
performed using Stata version 13.1 software (Stata-
Corp LP, College Station, Texas). 
RESULTS 
person-years of follow-up for all-cause mortality. 
There were 359 deaths over a median follow-up 
time of 1.47 (interquartile range: 0.51 to 2.68) years. 
Kaplan-Meier survival estimates were different 
across tertiles of admission chloride level (log-rank 
p < 0.001 for all) (Central Illustration). There were 
164, 127, and 68 deaths for tertiles 1 to 3, respectively. 
BASELINE CHARACTERISTICS. Baseline characteris- Tertile 1 had a higher death incidence rate of 
tics for the Cleveland Clinic and University of Penn- 0.22 death/person-years compared with tertiles 
sylvania cohorts are shown in Tables 1 and 2, 
respectively. For the Cleveland Clinic cohort, admis-
sion chloride levels were normally distributed, with 
median and mean admission chloride being 101 (in-
terquartile range: 97 to 104) mEq/1 and 100 ± 6 mEq/1, 
2 and 3 with 0.14 and 0.10 death/person-years, 
respectively. 
Per the univariable and multivariable proportional 
hazards models (Table 3), admission chloride levels 
were inversely associated with mortality (p < 0.001). 
respectively. As expected, admission chloride levels Every unit increase in chloride was associated with an 
were directly correlated to admission sodium levels (p 
o.61; p < 0.001) and negatively correlated to 
admission bicarbonate levels (p 0.39; p < 0.001). 
Higher chloride levels were positively associated with 
increasing LV ejection fraction, beta-blocker and 
renin-angiotensin system-blocker use, and renal 
dysfunction, but negatively associated with markers 
of neurohormonal activation (blood urea nitrogen and 
N-terminal pro-B-type natriuretic 
-6% relative improvement in survival (HR per unit 
change: 0.94; 95% CI: 0.92 to 0.95; p < 0.001). 
Although admission sodium levels were also 
inversely associated with mortality (HR per unit 
change: 0.95; 95% CI: 0.93 to 0.97; p < 0.001), 
admission chloride levels showed greater discrimi-
nation for mortality (C statistic: o.60; 95% CI: 0.57 to 
o.64) than admission sodium levels (C statistic: 0.56; 
95% CI: 0.53 to 0.59; p < 0.001). There was no 
TABLE 1 Baseline Cbaracteristlcs of the aeveland Clink Cohort 
Age, yrs 
Male 
!scheme cardiomyopathy 
LVEF, % (n 1,068) 
SBP, mm Hg 
Beta blocker 
RAS blocker 
MRA 
Sodlt.m, mEq/l 
Bicarbonate, mEq/l 
BUN, mg/dl 
Creatinine, mg/dl 
Total (N 1,318) 
68.7 (59.1 to 77.2) 
70.0 
3411 
27 (19 to 45) 
118 (105 to 137) 
84.9 
59.2 
363 
137 (135 to 140) 
25 (22 to 27) 
27 (19 to 40) 
1.28 (0.99 to 1.69) 
<99 (n 456) 
67 .9 (59.2to 76.2) 
71.9 
33.6 
25 (15 to 40) 
111 (102 to 128) 
80.3 
52.2 
43.4 
134 (131 to 137) 
17 (24 to 30} 
31 (22 to 47) 
1.33 (1.04 to 1.77) 
Admission CNoride (mEq/1) 
99 to 103 (n 497) 
68.4 (58.7 to 77 3} 
6911 
38.2 
25 (20 to45) 
120 (105 to 137) 
88.3 
62.2 
36.0 
138 (136 to 149} 
25 (23 to 27) 
27 (19 to 38) 
1.29 (0.96 to 1.71) 
NT proBNP, pg/ml (n 481) 
Hemoglobin, g/dl 
4,817 (2,415 to 9,536} 5,793 (3,133 to 10,418) 4,268 (2,180 to 9,175) 
Total bilirubin, mg/dl 
Length of stay, days 
<\Weight during admission, kg 
11.6 (10.1 to 13.1) 
0.8 (0.5 to 13) 
8.7 (S.O to 16.7) 
2.5 ( 6.0 to 0.1) 
11.6 (10.2 to 13.2) 
1.0 (0.6 to 1.5) 
9.7 (5.5 to 19.4} 
2.9 ( 6.8 to o.o) 
11.7 (10.2 to 13.2} 
0.8 (0.5 to 1.3} 
9.0 (4.9 to 1711} 
211 ( 63 to 0.0) 
V.lues are median Onterquartlle range) or %. 'P val.u, for the Jond<heere-T"'tra or Cuzid< tests of trend. 
>103 (n 365) 
695 (60.1 to 78.2} 
67.7 
31.5 
34 (20 to 50) 
127 (113 to 144} 
86.0 
63.8 
28.0 
138 (138 to 142) 
23 (21 to 25} 
25 (18 to 34} 
1.20 (0.98 to 1.60} 
4,684 (2,428 to 8,644) 
113 (9. 7 to 12. 7) 
011 (05 to 1.1} 
7.9 (4.9 to 14.1) 
15 ( 4.4 to 03) 
p Vllue• 
0.09 
0.19 
0.64 
< 0.001 
< 0.001 
0.01 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
0.004 
0.044 
0.003 
< 0.001 
< 0.001 
< 0.001 
BUN blood Ul'N nitrog@l1; LVEF left ventnQllar 4'ection fraction; MRA rnineratoaw1ic:d antagonist; tfl'•proBNP N-tenninal pn,-B•type natril.l'etic p,¢de; 
RAS reni.,..ngioten!in system; SBP systolic blood pressi.re. 
TABLE 2 Baseline Characteristics of the University of Pennsylvania Cohort 
Age, yrs 
Male 
lschemic cardiomyopathy 
LVEF,% 
SBP, mm Hg 
Beta blocker 
RAS blocker 
MRA 
Sodium, mEq/l 
Bicarbonate, mEq/l 
BUN, mg/dl 
Creatinine, mg/dl 
BNP, pg/ml 
Hemoglobin, g/dl 
Total bilinbn , mg/dl 
Length of stay, days 
t.Weight during admission, kg 
Total (N 876) 
62.9 (51.4 to 743) 
54.3 
24.2 
27.S (15 to 475) 
135 (115 to 158) 
67.4 
61.2 
15.1 
139 (137 to 141) 
25 (23 to 28) 
22 (15 to 34) 
1.3 (1.0 to 1.7) 
1,314 (673 to 2,435) 
123 (10.7 to 13.6) 
0.8 (05 to 1.4) 
5 (4 to 8) 
3.1 ( 5.9 to 0.8) 
<101 (n 253) 
64.9 (53.8 to 74.8) 
60.1 
33.6 
27.5 (15 to 50) 
120 (102to 143) 
715 
60.9 
225 
136 (133 to 139) 
28 (25 to 31) 
30 (18 to48) 
1.40 (1.0 to 1.8) 
1,372 (715 to 2,845) 
12.2 (10.6 to 13.7) 
0.9 (0.6 to 1.7) 
6 (4 to 9) 
2.6 ( 5.9 to 0.7) 
Adnuion 0.loride (mE.q/1) 
101 ID 104 (n 262) 
59.2 (483 to 72.7) 
59.2 
16.8 
25 (15 to 45) 
138 (118 to 161) 
66.4 
63.7 
14.1 
139 (137 to 141) 
26 (24 to 28) 
205 (15 to 27) 
1.2 (1.0 to 15) 
1,241 (649 to 2,113) 
12.6 (11.0 to 13.9) 
0.9 (0.5 to 1.4) 
5 (4 to 8) 
3.2 ( 6.4 to 0.9) 
>104 (n 361) 
64.5 (523 to 75.6) 
46.8 
23.0 
30 (15 to 47 5) 
145 (126 to 166) 
65.1 
59.6 
10.5 
141 (139 to 142) 
24 (21 to 26) 
21 (14 to 33) 
1.3 (1.0 to 1.7) 
1,319 (671 to 2,389) 
12.1 (10.6 to 135) 
0.7 (0.4 to 1.0) 
5 (4 to 7) 
3.4 ( 5.4 to 0.7) 
p Value• 
0.67 
0.001 
0.01 
0.48 
< 0.001 
0.10 
0.67 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
0.19 
0.86 
0.44 
< 0.001 
< 0.001 
0.55 
values are median (interquartile range) or%. •p value for the .lond<tieere•Terstra or Qaidc tests of trend. 
BNP 11-l)pe natriln!lic peptide; olher -eviatlons as in Table I. 
CENTRAL ILLUSTRATION Chloride in Acute Decompensated Heart Failure: Survival Est.imates by Admission Chloride Levels 
1.00 
0.75 
-ro 
> 
> 
... 
a.so 
:::, 
V, 
0.25 
Admission Chloride [mEq/ l] 
- Tertile 1, <99 
- Tertile 2, 99-103 
Tertile 3, >103 
0.00 Log-rank, Chi-square 36.7, p <0.001 
0 1 2 3 
Years 
At-risk by Chloride Tertile 
Tertile 1 456 235 148 82 
Tertile 2 497 319 203 95 
Tertile 3 365 243 147 78 
Grodin, J.L. et al. J Am Coll Cardiel. 2015: 66(6):659-66. 
For the Cleveland Clinic cohort, Kaplan Meier survival estimates significantly differed across tertiles of admission chloride level (log rank p < 0.001) , with 
worse survival for lower admission chloride levels. 
significant interaction between admission chloride 
and sodium levels for mortality (p 0.19). Kaplan-
Meier survival estimates stratified by admission 
hypochloremia (chloride <96 mEq/1) and hypona-
tremia (sodium <134 mEq/1) are shown in Figure 1, 
which graphically illustrates that chloride levels may 
have a stronger prognostic role than sodium levels. 
After multivariable adjustment, admission chloride 
levels remained independently inversely associated 
with mortality (HR per unit change: 0.93; 95% CT: 
0.90 to 0.97; p < 0.001) (Figure 2). Mortality risk 
increased with decreasing chloride levels below -96 
mEq/1 and did not significantly differ at values >96 
mEq/1. There was no increase in the overall C statistic 
of the multivariable model with the addition of 
chloride (o.68 vs. o.69; p 0.5). However, adding 
chloride to the multivariable model did significantly 
reclassify risk (integrated discrimination 
improvement, 10%; p < 0.001; category-free net-
reclassification indexes, 17.2%; p 0.006). With 
additional adjustment for weight change and blood 
urea nitrogen/creatinine ratio, admission chloride 
levels remained significantly associated with 
mortality (HR per unit change: 0.93; 95% CI: 0.90 to 
0.97; p < 0.001). 
However, after multivariable adjustment for 
other variables including admission chloride levels, 
admission sodium levels were not independently 
associated with mortality (HR per unit change: 1.03; 
95% CT: 0.99 to 1.07; p 0.18). Discharge chloride 
level was significant when substituted for admission 
chloride level (discharge sodium level was sub-
stituted for admission sodium level) in the multivar-
iable model for mortality (HR per unit change: 0.94; 
95% CT: 0.92 to 0.97; p < 0.001) and is graphically 
depicted in Figure 3. 
To validate our present findings, we turned to an 
independent acute HF cohort from the University of 
Pennsylvania with longer follow-up (Table 3). Admis-
sion chloride distribution was comparable with our 
study cohort (median: 103 [100 to 106) mEq/1; mean: 
103 ± 6 mEq/l). Baseline characteristics of this valida-
tion cohort are presented in Table 2. Similar to the 
Cleveland Clinic cohort, admission chloride levels 
were directly correlated to admission sodium (p 0.54; 
p < 0.001) and negatively correlated to admission bi-
carbonate levels (p ·0.49; p < 0.001). There were 453 
deaths out of 876 patients with 3,038 person-years of 
follow-up for all-cause mortality. In contrast to the 
derivation cohort, admission chloride levels violated 
the proportional hazards assumption (p > 0.1) and 
were thus analyzed as a Heaviside function with time 
stratified at 1 year. Admission chloride levels were 
inversely associated with 1-year mortality in unad-
justed (HR per unit change: 0.93; 95% CI: 0.91 to 0.95; 
TA8LE3 Unlvarlable and Multlvarlable Cox Proportional Hazards Models for Mortallty 
Univ-1,lo M .. tlv.-
HR 95% 0 p Value HR 9 S% CI p Valuo 
Cleveland Clinic Cohort 
O,loride, mEq/l 0.94 0.92 0.95 < 0.001 0.93• 0.90 0.97 <0.001 
Sodium, mEq/l 0.95 0.93 0.97 < 0.001 
Log BUN, mg/dl 259 2.14 3.14 < 0.001 2.00• 1.61 2.48 <0.001 
lschemic cardiomyopathy 136 1.10 1.68 0.004 
Beta blocker 0.74 056 0.97 0.028 
RAS blocker 0.77 0.63 0.95 0.015 
SBP, mm Hg 0.991 0.986 0.995 < 0.001 0.993· 0.988 0.998 o.m 
Age, yrs 1.02 1.011.03 < 0.001 1.02• 1.011.03 <0.001 
Bicarbonate, mEq/l 1.03 1.011.06 0.011 
Length of stay, days 1.002 0.999 1.005 0.14 
University of Pennsylvania Cohort 
O,loride, mEq/l :S1 yr 0.93t 0.91 0.95 <00.001 0.95t 0.92 0.99 0.01 
Chloride, mEq/l >1 yr 0.99t 0.971.02 0.56 
Sodium, mEq/l 0.96 0.94 0.98 < 0.001 
Log BUN, mg/dl 2.13 1.83 2.48 < 0.001 1.60 1.34 1.91 <0.001 
lschemic cardiomyopathy 1.48 1.211.81 < 0.001 
Beta blocker 1.15 0.941.41 0.16 
RAS blocker 0.96 0.79 1.15 0.63 
MRA 1.14 0.88 1.47 0.33 
SBP, mm Hg 0.994 0.991 0.997 < 0.001 0.996 0.992 0 .999 0.01 
Age, yrs 1.032 1.026 1.039 <0.001 1.03 1.02 1.04 <0.001 
Bicarbonat e, mEq/l 1.01 0.99 1.03 0.337 
Length of stay, days 1.05 1.02 1.08 0.001 1.03 1.00 1.07 0.04 
'Within-stral\Jln estinate stratified by MRA use. tHRs rf$>crted b" both Heavi!ide functions in sane model. 
Cl a,nfidence interr.il; HR har.ard ratio; other ~reviations as in Tallle L 
p < 0.001) and adjusted analysis (HR per unit change: 
0.95; 95% CT: 0.92 to 0.99; p 0.01). Additionally, the 
adjusted association with admission sodium levels 
was not significant (HR per unit change: 0.99; 95% CI: 
l'IOUAE 1 Survival Estimates Stratified by Admission 
Hypochloremla and Hyponatremla 
1.00 
0.75 
j 
·s: 0.50 
:5 
VI 
- Chlaide <96 and Sodium <134 
- Chloride <96 and Sodium i 134 
0.25 - Chlaide >96 and Sodium <134 
- Chlondo >96 and Sodium s 134 
0.00 Log-rank, chi-square 36.7 , p < .001 
0 
At-risk by Chloride and Sodium Level [mEQ/1] 
Chlondo <96 and Sodium <134 148 
Chloride <96and Sodium i134 86 
Chloride ~96 and Sodium <134 84 
Chlondoe96andSodiume134 1000 
97 
61 
71 
838 
Years 
2 
91 
55 
67 
791 
3 
85 
54 
66 
766 
Kaplan Meier survival curve estimates d.assified by levels of chloride (< or a:96 mEq/l} and 
sodium(< or a:134 mEq/0 on admission demonstrate that chloride levels may provide a 
stronger prognosis role than sodium levels. 
"IOURE 2 Mortality Risk per Adjusted Admission 
Chloride Levels 
4 a 95%CI 
- Fitted ( UIVE! 
-2 
L,------,-----,-----,-----, 
80 90 100 110 120 
Admission Chloride [mEq/l] 
A fitted curve was generated from residual estimates according 
to admission chloride level at the Cleveland CUnic after multi 
variable adjustment for sodium, length of stay, bicarbonate, 
blood urea nitrogen, age, ischemic cardiomyopathy, and drug use 
(beta blocker, renin angiotensin system blocker, and mineralo 
corticoid antagonist). Cl confidence interval. 
0_96 to 1-03; p 0.58). Similar to the Cleveland Clinic 
cohort, discharge chloride level was significant when 
substituted for admission chloride level (discharge 
sodium level was substituted for admission sodium 
level) to the multivariable model for mortality (HR per 
unit change: 0.97; 95% CI: 0.95 to 0.99; p 0.01). 
DISCUSSION 
In 2 contemporary cohorts of patients predomi-
nantly with systolic dysfunction hospitalized for 
.,,ouRE 3 Mortality Risk per Adjusted Discharge 
Chloride Levels 
4 
'o i 2 
ex 
a 95%CI 
- l=ltted Cuive 
-2 
'-,-----,-----,-----,-----, 
80 90 100 110 120 
Discharge Cltorlde [mEq/\1 
A fitted curve was generated from residual estimates according 
to discharge chloride level at t he Cleveland CUnic after multi 
variable adjustment for sodium, length of stay, bicarbonate, 
blood urea nitrogen, age, ischemic cardiomyopathy, and drug use 
(beta blocker, renin angiotensin system blocker, and mineralo 
corticoid antagonist). Cl confidence interval. 
ADHF and electrolyte measures, we report several 
key findings that highlight prognostic implications 
of serum chloride. First, serum chloride levels were 
independently and inversely associated with mor-
tality after multivariable adjustment for other 
prognostic factors including serum sodium concen-
tration. Second, serum chloride levels modestly 
enhanced mortality prediction compared with so-
dium levels. Furthermore, serum sodium levels 
were no longer associated with mortality when 
serum chloride levels were added to the multivari-
able model. Finally, although modestly correlated, 
serum chloride and serum sodium levels had no 
significant interaction for mortality prediction. 
These findings highlight the prognostic implications 
of serum chloride level in ADHF and suggest that it 
provides stronger prognostic information than 
serum sodium level. Further investigations into the 
clinical relevance of hypochloremia in the setting of 
acute HF are warranted. 
The pathological role of chloride in HF is incom-
pletely understood, in part because chloride levels 
have been rarely documented in clinical trials or 
registries. Chloride accounts for approximately one-
third of the tonicity and two-thirds of all negative 
charges in the plasma (21). Dietary sodium chloride 
is the main source of chloride in the body and its 
removal is facilitated by gastric, sweat, and renal 
excretion. Serum chloride levels may represent the 
downstream effects of adversely prognostic mal-
adaptive neurohormonal, renal, and acid-base dis-
turbances in HF. Indeed, mechanisms that reduce 
sodium levels can similarly lower chloride levels 
(22). These include: 1) the pathological impairment 
of free water excretion resulting from increased 
nonosmotic release of arginine vasopressin (23), 
which is typically increased in patients with symp-
tomatic HF (24,25); 2) the pleotropic effects of 
excess angiotensin II on renal sodium and water 
handling and neural thirst center activation (1); and 
3) increased baroreceptor-mediated release of argi-
nine vasopressin (24). All of these mechanisms are 
directly stimulated in HF (26). As a result, lower 
chloride levels may be dilutional in nature. Yet they 
may also represent a state of electrolyte depletion, 
especially when chloride is lower relative to sodium, 
which can occur in the setting of diuretic-induced 
salt wasting as chloride is excreted in the urine 
while bicarbonate is retained to maintain electro-
neutrality (27). Making this distinction may have 
clinical implications when administering de-
congestive therapies for acute HF (28). 
Both sodium and chloride levels were prog-
nostically similar in unadjusted, but not adjusted, 
analyses, potentially suggesting a pathophysiolog-ical with ADHF and established HF based on the history 
difference in the 2 electrolytes. In the presence of HF, of an ICD. Data were Jacking regarding patient-level 
the relative concentrations of sodium and chloride in decision making and resulting medication changes 
the plasma compartments can be Jow-ered and the impact they would have on changing chlo-
symmetrically or asymmetrically (29,30). This may ride levels and prognosis. Similarly, the impact of 
be related to the ability of the kidney to excrete these chloride levels on HF rehospitalizations could not be 
electrolytes and modified by thera-peutic measures determined. There was only a minority of patients 
(loop diuretics) and comorbid conditions. Chloride is a with serum chloride levels >107 mEq/1, and this 
buffer for cations, in-eluding acid and sodium, and analysis was underpowered to determine increased 
plays a major role in the ability of the kidney to risk caused by hyperchloremia. To our knowledge, 
eliminate salt and water. Therefore, in contrast to 
sodium, chloride has a stronger prognostic role 
because it may play a broader homeostatic role. 
Our finding that lower chloride levels during 
admission were associated with higher mortality of-
fers important insights into interpretation of elec-
trolytes in ADHF. Our findings suggest that although 
however, therapies that increase serum chloride 
concentrations, such as hypertonic saline, are rarely 
used in ADHF populations, but the potential impact 
of potassium supplementation with potassium ch-
loride is unclear. Nevertheless, this large, well-
powered ADHF cohort confers a new perspective 
on serum chloride levels and their impact on 
sodium levels are important, more robust prognostic prognosis. 
information can be inferred from serum chloride levels. 
Although low sodium has consistently been shown to CONCLUSIONS 
be a strong predictor of short- and Jong-term morbidity 
and mortality in patients with both systolic and Serum chloride levels measured during hospitaliza-
diastolic HF (7,u,13,31,32), there was little tion for ADHF are independently and inversely asso-
mention of the impact of chloride on the interpretation dated with Jong-term mortality. This association was 
of sodium levels in these analyses. As our results independent of, and added incremental prognostic 
suggest, these previous results may have failed to take information to, serum sodium levels. These findings 
into account serum chloride levels. highlight the clinical significance of chloride, a rou-
Prior evidence for the prognostic role of chloride is tinely measured electrolyte, in Jong-term prognosti-
sparse, and there is no formalized definition of cation for ADHF. 
hypochlorernia in HF. Our observations highlight the 
need to focus on better understanding of chloride 
homeostasis and preserving it as a potential thera- REPRINT REQUESTS AND CORRESPONDENCE: Dr. 
peutic consideration, particularly in the setting of W.R. Wilson Tang, Heart and Vascular Institute, 
ADHF with extensive use of loop diuretics that Cleveland Clinic, 9500 Euclid Avenue, Desk 13-4, 
primarily inhibit the sodium-potassium-chloride Cleveland, Ohio 44195. E-mail: tangw@ccf.org OR 
cotransporter leading to inevitable and excessive Dr. Jeffrey M. Testani, Yale University, 60 Temple 
chloride wasting. Street, Suite 6C, New Haven, Connecticut 06510. 
STUDY LIMITATIONS_ Our results must be inter-preted 
in the context of several limitations in our study 
design. We cannot exclude the presence of selection 
b ias for those undergoing evaluation and treatment for 
ADHF at 2 tertiary care centers. How-ever, the external 
validity of these findings is st-rengthened with the 
addition of the validation cohort. These patients 
largely had systolic dysfunc-tion with questionable 
generalizability to an ADHF population with preserved 
L V systolic function. Yet this also afforded an 
opportunity for a diversity of pathology in a 
contemporary cohort recorded by a modem electronic 
medical record to be retrieved in a very efficient 
manner. Our analysis also displayed a unique way of 
identifying patients presenting 
E-mail: jeffrey.testani@yale.edu. 
PERSPECTIVES 
COMPETENCY IN PATIENT CARE AND PROCEDURAL 
SKILLS: Like hyponatremia, hypochloremia in pat ients 
hospitalized for ADHF is independently associated with 
long-term mortality. 
TRANSLATIONAL OUTLOOK: Additional clinical and 
mechanistic studies are needed to investigate t he pathophysi-
ology of electrolyte deplet ion in patients with ADHF and develop 
therapeutic st rategies that avoid the adverse consequences 
associated with hypochloremia. 
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